Cargando…

Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway

BACKGROUND: Opioid dependence carries the highest disease burden of all illicit drugs. Opioid agonist therapy (OAT) is an evidence-based medical intervention that reduces morbidity and mortality. There is limited knowledge on the health-related quality of life (HRQoL) of long-term patients in OAT. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Aas, Christer Frode, Vold, Jørn Henrik, Skurtveit, Svetlana, Lim, Aaron G., Ruths, Sabine, Islam, Kamrul, Askildsen, Jan Erik, Løberg, Else-Marie, Fadnes, Lars Thore, Johansson, Kjell Arne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469909/
https://www.ncbi.nlm.nih.gov/pubmed/32883319
http://dx.doi.org/10.1186/s13011-020-00309-y
_version_ 1783578488289099776
author Aas, Christer Frode
Vold, Jørn Henrik
Skurtveit, Svetlana
Lim, Aaron G.
Ruths, Sabine
Islam, Kamrul
Askildsen, Jan Erik
Løberg, Else-Marie
Fadnes, Lars Thore
Johansson, Kjell Arne
author_facet Aas, Christer Frode
Vold, Jørn Henrik
Skurtveit, Svetlana
Lim, Aaron G.
Ruths, Sabine
Islam, Kamrul
Askildsen, Jan Erik
Løberg, Else-Marie
Fadnes, Lars Thore
Johansson, Kjell Arne
author_sort Aas, Christer Frode
collection PubMed
description BACKGROUND: Opioid dependence carries the highest disease burden of all illicit drugs. Opioid agonist therapy (OAT) is an evidence-based medical intervention that reduces morbidity and mortality. There is limited knowledge on the health-related quality of life (HRQoL) of long-term patients in OAT. This study measures HRQoL and self-perceived health of long-term patients on OAT, compares the scores to a Norwegian reference population, and assesses changes in these scores at 1-year follow up. METHODS: We conducted a nested prospective cohort study among nine OAT outpatient clinics in Norway. 609 OAT patients were included, 245 (40%) followed-up one year later. Data on patient characteristics, HRQoL, and self-perceived health was collected. HRQoL was assessed with the EQ-5D-5L, which measures five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) on a five-point Likert scale (from “no problems” to “extreme problems”). An UK value set was applied to calculate index values (from 0 to 1) for the EQ-5D-5L and compare them to a Norwegian reference population. Self-perceived health was measured with EQ-VAS (from 0 to 100). RESULTS: Mean (standard deviation (SD)) EQ-5D-5L index value at baseline was 0.699 (0.250) and EQ-VAS 57 (22) compared to 0.848 (0.200) and 80(19) for the Norwegian reference population. There were large variations in EQ-5D-5L index values, where 43% had > 0.8 and 5% had < 0.2 at baseline. The lowest EQ-5D-5L index values were observed for female patients, age groups older than 40 years and for methadone users. At follow-up, improvements in HRQoL were observed across almost all dimensions and found significant for mobility and pain/discomfort. Mean (SD) overall index value and EQ-VAS at follow up were 0.729 (0.237) and 59 (22) respectively. CONCLUSION: The average HRQoL and self-perceived health of OAT patients is significantly lower than that of the general population, and lower than what has been found among other severe somatic and psychiatric conditions. Around 34% had very good HRQoL, higher than average Norwegian values, and around 5% had extremely poor HRQoL.
format Online
Article
Text
id pubmed-7469909
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74699092020-09-08 Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway Aas, Christer Frode Vold, Jørn Henrik Skurtveit, Svetlana Lim, Aaron G. Ruths, Sabine Islam, Kamrul Askildsen, Jan Erik Løberg, Else-Marie Fadnes, Lars Thore Johansson, Kjell Arne Subst Abuse Treat Prev Policy Research BACKGROUND: Opioid dependence carries the highest disease burden of all illicit drugs. Opioid agonist therapy (OAT) is an evidence-based medical intervention that reduces morbidity and mortality. There is limited knowledge on the health-related quality of life (HRQoL) of long-term patients in OAT. This study measures HRQoL and self-perceived health of long-term patients on OAT, compares the scores to a Norwegian reference population, and assesses changes in these scores at 1-year follow up. METHODS: We conducted a nested prospective cohort study among nine OAT outpatient clinics in Norway. 609 OAT patients were included, 245 (40%) followed-up one year later. Data on patient characteristics, HRQoL, and self-perceived health was collected. HRQoL was assessed with the EQ-5D-5L, which measures five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) on a five-point Likert scale (from “no problems” to “extreme problems”). An UK value set was applied to calculate index values (from 0 to 1) for the EQ-5D-5L and compare them to a Norwegian reference population. Self-perceived health was measured with EQ-VAS (from 0 to 100). RESULTS: Mean (standard deviation (SD)) EQ-5D-5L index value at baseline was 0.699 (0.250) and EQ-VAS 57 (22) compared to 0.848 (0.200) and 80(19) for the Norwegian reference population. There were large variations in EQ-5D-5L index values, where 43% had > 0.8 and 5% had < 0.2 at baseline. The lowest EQ-5D-5L index values were observed for female patients, age groups older than 40 years and for methadone users. At follow-up, improvements in HRQoL were observed across almost all dimensions and found significant for mobility and pain/discomfort. Mean (SD) overall index value and EQ-VAS at follow up were 0.729 (0.237) and 59 (22) respectively. CONCLUSION: The average HRQoL and self-perceived health of OAT patients is significantly lower than that of the general population, and lower than what has been found among other severe somatic and psychiatric conditions. Around 34% had very good HRQoL, higher than average Norwegian values, and around 5% had extremely poor HRQoL. BioMed Central 2020-09-03 /pmc/articles/PMC7469909/ /pubmed/32883319 http://dx.doi.org/10.1186/s13011-020-00309-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Aas, Christer Frode
Vold, Jørn Henrik
Skurtveit, Svetlana
Lim, Aaron G.
Ruths, Sabine
Islam, Kamrul
Askildsen, Jan Erik
Løberg, Else-Marie
Fadnes, Lars Thore
Johansson, Kjell Arne
Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway
title Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway
title_full Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway
title_fullStr Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway
title_full_unstemmed Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway
title_short Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway
title_sort health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in norway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469909/
https://www.ncbi.nlm.nih.gov/pubmed/32883319
http://dx.doi.org/10.1186/s13011-020-00309-y
work_keys_str_mv AT aaschristerfrode healthrelatedqualityoflifeoflongtermpatientsreceivingopioidagonisttherapyanestedprospectivecohortstudyinnorway
AT voldjørnhenrik healthrelatedqualityoflifeoflongtermpatientsreceivingopioidagonisttherapyanestedprospectivecohortstudyinnorway
AT skurtveitsvetlana healthrelatedqualityoflifeoflongtermpatientsreceivingopioidagonisttherapyanestedprospectivecohortstudyinnorway
AT limaarong healthrelatedqualityoflifeoflongtermpatientsreceivingopioidagonisttherapyanestedprospectivecohortstudyinnorway
AT ruthssabine healthrelatedqualityoflifeoflongtermpatientsreceivingopioidagonisttherapyanestedprospectivecohortstudyinnorway
AT islamkamrul healthrelatedqualityoflifeoflongtermpatientsreceivingopioidagonisttherapyanestedprospectivecohortstudyinnorway
AT askildsenjanerik healthrelatedqualityoflifeoflongtermpatientsreceivingopioidagonisttherapyanestedprospectivecohortstudyinnorway
AT løbergelsemarie healthrelatedqualityoflifeoflongtermpatientsreceivingopioidagonisttherapyanestedprospectivecohortstudyinnorway
AT fadneslarsthore healthrelatedqualityoflifeoflongtermpatientsreceivingopioidagonisttherapyanestedprospectivecohortstudyinnorway
AT johanssonkjellarne healthrelatedqualityoflifeoflongtermpatientsreceivingopioidagonisttherapyanestedprospectivecohortstudyinnorway
AT healthrelatedqualityoflifeoflongtermpatientsreceivingopioidagonisttherapyanestedprospectivecohortstudyinnorway